BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liang CM, Hu TH, Lu SN, Hung CH, Huang CM, Wang JH, Yen YH, Chen CH, Chang KC, Tsai MC. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy. J Viral Hepat. 2013;20:761-769. [PMID: 24168255 DOI: 10.1111/jvh.12097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
Number Citing Articles
1 Yamamoto S, Fukuhara T, Ono C, Uemura K, Kawachi Y, Shiokawa M, Mori H, Wada M, Shima R, Okamoto T, Hiraga N, Suzuki R, Chayama K, Wakita T, Matsuura Y. Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus. PLoS Pathog. 2016;12:e1005610. [PMID: 27152966 DOI: 10.1371/journal.ppat.1005610] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 8.8] [Reference Citation Analysis]
2 Kuo MT, Hu TH, Lu SN, Hung CH, Wang JH, Chen CH, Chiu YC, Lee CM. Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin therapy for chronic hepatitis C. Dis Markers 2014;2014:462958. [PMID: 25505815 DOI: 10.1155/2014/462958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Yu YC, Wang Y, He CL, Wang MR, Wang YM. Management of hepatitis C virus infection in hemodialysis patients. 1948-5182 2014; 6(6): 419-425 [PMID: 25018852 DOI: 10.4254/wjh.v6.i6.419] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]